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Summary: Factors of the classical complement pathway, the contact system and fibrinolysis were evaluated
both with functional and immunochemical methods, in patients with inherited deficiency of Cl-inhibitor.
Evaluations were performed under basal conditions, during acute attacks and during prophylaxis with low
doses of anabolic steroids. Patients in the basal state showed no significant abnormalities of any of the
parameters that we investigated. During acute attacks a slightly reduced prekallikrein concentration was
registered. During treatment with low doses of danazol and stanozolol, protein C and plasminogen were
found to be increased. Our data suggest that Cl-inhibitor deficiency per se does not lead to a derangement
of the fibrinolysis and coagulation contact system, and that the kinin system may be involved during acute
attacks of angioedema.
Introduction
Patients with hereditary angioedema have recurrent
episodes of non-inflammatory swelling involving sub-
cutaneous tissues, the upper airway mucosa and gas-
trointestinal tract. Death may result from obstruction
of the larynx.
The biochemical abnormality is the deficiency of the
inhibitor of the first component of complement (Cl*
inhibitor) which is inherited as an autosomal domi-
nant trait (1). Eighty percent of the patients have the
predominant form (type I) of the disease, with low
antigenic and functional plasma concentrations of Cl-
inhibitor, the remaining 15% having the variant form
(type II) with low functional activity only (2). Cl-
inhibitor inhibits not only the proteolytic activity of
Cl but also several enzymes of the haemostasis con-
tact phase and fibrinolysis (3). The clinical observa-
tions that potentially profibrinolytic stimuli such as
emotional or physical stress may trigger attacks of
angioedema (4), that antifibrinolytic agents (ε-ami-
nocaproic acid, tranexamic acid) are effective for pro-
phylaxis in hereditary angioedema (5), that plasmin
seems to be necessary for the release of permeability
mediator in hereditary angioedema (6) and that the
contact system may be activated during acute attacks
(7) could indicate that fibrinolysis and the haemostasis
contact phase may both be implicated in the patho-
genesis of the disease. This intricate problem has been
discussed by several investigators (7 — 11) but there
are no definitive data in the literature. In this study
we investigated the possibility of changes in coagu-
lation and fibrinolytic systems in hereditary angio-
edema patients under basal conditions, and during
acute attacks, using an extensive number of immu-
nological and biological tests. Moreover, in a group
of hereditary angioedema patients under long-term
treatment with low doses of 17-a-alkylated androgens
we evaluated whether these drugs could influence the
contact system or the fibrinolysis parameters. In fact,
high doses of anabolic steroids modified the blood
concentrations of various components of the coagu-
lation and fibrinolytic systems (12—15).
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Patients and Methods
Pat ien ts
Three groups of patients with type I hereditary angioedema
were studied:
1)17 asymptomatic patients (10 females and 7 males, age range
12 — 56) without any treatment for at least 2 months;
2) 4 untreated patients (all females, age range 27-52) during
acute attacks, involving the abdomen in 2 patients, the rigth
arm in 1 patient and the right arm and left leg in 1 patient
(blood samples were taken from one to three hours after the
beginning of the attack);
3) 10 patients (4 females and 6 males, age range 25-61) on
long term therapy with minimal effective doses of stanozolol
2-3 mg/day (6 patients) or danazol 100-200 mg/day (4 pa-
tients) for periods ranging from 6 months to 4 years.
A reference group consisted of 12 healthy donors (6 females
and 6 males, age range 20 — 34).
Samples
All plasma samples were prepared by collecting nine volumes
of whole blood through a 19G butterfly cannula into one
volume of 38 g/1 trisodium citrate in plastic tubes, without stasis
and discarding the first 2 ml of blood. Blood samples were
taken in the morning before 11 a.m., after an overnight fast
and a rest of 15 min. Platelet-poor plasma was obtained by
immediately centrifuging the blood at 4 °C at 2000 g for 30
min. Plasma was then aliquoted into plastic tubes, snap frozen
in a mixture of solid carbon dioxide and methanol and stored
at -80°C until use.
Funct ional assays
— Factor XII coagulant activity was measured by a one stage
bioassay based on the activated partial thromboplastin time
with a plasma congenially deficient in factor XII (16).
— Prekallikrein was determined by a spectrophotometric assay,
with control tests ensuring optimal conversion of prekallikrein
to kallikrein by the dextran sulphate method (17).
— Fibrinogen was determined by the method of Clauss (18).
— Plasminogen was assessed by the streptokinase-activation
procedure with the chromogenic substrate S-2251 (Kabi-Vi-
trum) (19); we calculated the concentration of free plasminogen
from the equilibrium:
Plasminogen · Histidine rich glycoprotein ^± Plasminogen +
Histidine rich glycoprotein (20).
— Tissue plasminogen activator activity in the euglobulin frac-
tion of plasma was measured by an indirect spectrophotometric
assay in the presence of cyanogen bromide fragments of fibri-
nogen (stimulator), plasminogen and synthetic plasmin sub-
strate S 2251 (Kabi Vitrum) (21).
— Tissue plasminogen activator inhibition of plasma was de-
termined by a modification of the tissue plasminogen activator
assay, as described by Verheijen (22).
— Antithrombin III activity was measured by a chromogenic
substrate technique, using the synthetic substrate S 2238 (Kabi
Vitrum) after full activation with heparin according to the
manufacturer's instructions.
— Cl-inhibitor was assayed by measuring esterolytic activity
towards the substrate, N-acetyl-L-tyrosine ethyl ester mono-
hydrate, according to Lachmann (23).
Immunochemical assays
— Factor XII, protein C and histidine-rich glycoprotein were
measured by the electroimmunoassays according to Laurell
(24), using monospecific antisera (antiserum against human
Factor XII — Nordic, antiserum against protein C kindly
provided by Dr. P. M. Mannucci, antiserum against human
histidine-rich glycoprotein manufactured in our laboratory).
— High molecular weight kininogen, antithrombin ΠΙ, Cl-
inhibitor and C4 antigens in plasma were determined by radial
immunodiff sion, as described by Mancini (25), using mono-
specific antisera (antiserum against light chain of human high
molecular weight kininogen — Nordic; antisera against anti-
thrombin III, Cl-inhibitor, C4 Behringwerke AG).
Statistics
The results were expressed as means ± standard deviation; the
significance of differences between means was assessed by the
two-tailed Student t test; when the distribution of data was not
normal (tissue type plasminogen activator activity and inhibi-
tion) the non-parametric test of Wilcoxon was used.
Results
All results are summarized in tables 1, 2 and 3.
Untreated hereditary angioedema patients
The mean level of Cl-inhibitor was 31% of normal,
based on functional activity, and 19% of normal,
based on antigen concentration (tab. 1); C4 antigen
level was 28% of normal. Functional levels of Cl-
inhibitor correlate with the antigen level (p < 0.001).
Both functional and immunochemical levels of Cl-
inhibitor correlate with C4 antigen levels (p < 0.001).
Haemostatic and fibrinolytic parameters were in the
normal range and did not differ from those of the
reference group (tabs. 2 and 3).
Hereditary angioedema patients during acute
attacks
Complement parameters were further decreased; in
two patients zero levels of C4 were recorded.
A decreased plasma concentration of prekallikrein
(p < 0.05) (tab. 2) was observed; no significant
changes were shown in the other studied components.
However, the levels of Factor XII and high molecular
weight kininogen tended to be lower (tab. 2).
The apparent increase in tissue-plasminogen activator
activity is due to the very high value of this parameter
in only one among the four pattents, and it is ob-
viously not statistically significant (tab. 3).
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Tab. 1. Complement parameters in
Cl -inhibitor antigen (%)
Cl -inhibitor activity (%)
C4 antigen (%)
Values are expressed as percentage
Tab. 2. Coagulation parameters in
Factor XII antigen (%)
Factor XII activity (%)
Prekallikrein (%)
High molecular weight kininogen
antigen (%)
Protein C antigen (%)
Antithrombin III activity (%)
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Values are expressed as percentage of a pool of normal plasma.
* p < 0.05
** Only 10 out of 17 untreated hereditary angioedema patients were available for determination of antithrombin III.
























































































* p < 0.005
** Only 11 out of 17 untreated hereditary angioedema patients were available for determination of tissue plasminogen activator
activity and inhibition.
Hereditary angioedema patients on long term
therapy with minimal effective doses of 17-
α-alkylated androgen
At low doses of androgen a slight increase of antigen
concentration of Cl-inhibitor (p < 0.025) was no-
ticed, with no 'Significant increase in either Cl-inhib-
itor functional activity or in C4 antigen (tab. 1).
The therapy resulted in increased packed cell volume
(p < 0.005), plasminogen (p < 0.005), free plasmin-
ogen (p < 0.005) and protein C (p < 0.05); a tend-
ency to increased antithrombin III functional levels
was also noticed (tabs. 2 and 3).
From the regression analysis between coagulation or
fibrinolytic parameters and Cl-inhibitor and C4 lev-
els, we observed that high molecular weight kininogen
correlated with Cl-inhibitor activity (p < 0.01) and
Cl-inhibitor antigen (p < 0.05) in hereditary angio-
edema patients, but not in normal subjects.
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Discussion
Only patients with the predominant form of heredi-
tary angioedema (type I) were studied to avoid the
different and unspecific interactions between the dys-
morphic Cl-inhibitor protein and the various com-
ponents of the studied systems (26).
With this study we demonstrated that the extrinsic
fibrinolysis and the haemostasis contact phase are not
affected in type I hereditary angioedema patients un-
der basal conditions. These data contrast with the
report by Cullmann of increased functional Factor
XII (10), and the opposite finding by Nilsson of low
functional Factor XII (9).
To support our result we must stress that we per-
formed the assay for Factor XII on 17 patients both
with functional and immunochemical methods, in or-
der to avoid a functional misestimation due to an in
vitro activatiorvof the contact phase. We can conclude
that despite the lack of such an important regulating
protein as Cl-inhibitor, other compensating factors
succeed in preventing gross activation under basal
conditions.
The nature of the pathogenetic plasma factors and
the mediators of attacks are still controversial. A
major question is whether the fibrinolytic or the kinin-
kallikrein system plays a key role in attacks. In vitro
experiments demonstrated that a major vasoactive
peptide, first found in hereditary angioedema plasma
during attacks (27). can be released probably from
C2 when this protein is incubated together with C4,
Cl and plasmin (11). The other hypothesis is that the
activation of the kallikrein, first proposed by Lander-
mann (28) and supported by detection of active kal-
likrein in suction blister fluid of hereditary angio-
edema patients (29), is a critical factor in attacks.
We failed to demonstrate major changes in the fibrin-
olytic system of plasma from hereditary angioedema
patients during attacks. We did, however, find a sig-
nificant reduction of prekallikrein and to a lesser
extent of Factor XII and high molecular weight kin-
inogen. The balance between synthesis and catabotism
can smooth variations in the plasma levels of each
factor, although this trend, consistent with the data
of Shapira (7), suggests an involvment of the kinin
system. The significant correlation between high mo-
lecular weight kininogen and Cl-inhibitor in patients
with hereditary angioedema but not in normal human
controls suggests that Cl-inhibitor, when at low levels,
becomes critical for the control of high molecular
weight kininogen metabolism.
In the group of patients treated with low doses of
anabolic steroids, only a rise in plasminogen concen-
trations (approx 30%) and protein C (approx 20%)
were observed, and there was no effect on the fibrin-
olytic system. This seems to be in accord with the
observation that both fibrinolysis inhibitors ( -ami*
nocaproic acid, tranexamic acid) and profibrinolytic
drugs (stanozolol, danazol) (12, 30, 31) are effective
in hereditary angioedema.
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